AGN News and Press, Allergan plc From 09/04/19

Satsuma Pharmaceuticals ( STSA ) has a product candidate at Phase 3 of development and is targeting a large market. With other competitors trading with a valuation of $0.6-1.5 billion, after the IPO, we expect the company to sell around these marks. Market participants will need to carefully r...

The Trump administration has allocated $1.8B to help states and local governments tackle opioid addiction in their respective areas. The funds will be distributed through Substance Abuse and Mental Health Services and the CDC for treatment and data gathering. More news on: Teva Pharmaceu...

The Stock Exchange is all about trading. Each week, we do the following: Discuss an important issue for traders, Highlight several technical trading methods, including current ideas, Feature advice from top traders and writers, and Provide a few (minority) reactions from fundamenta...

Only a few short days after the Allergan ( AGN ) acquisition was announced, AbbVie ( ABBV ) surged back to $75. The stock is now down $10 to $65 offering a very attractive and high 6.5% dividend yield while the market awaits the closure of the big biopharma deal. My original research on ...

Evolus, Inc. ( EOLS ) has recently started its commercial launch of the key product Jeuveau in the U.S. in May 2019, while the stock price has plummeted almost 50% in the meantime. We initiated our coverage on the stock with a BUY rating when the stock price was around $26.50 back in February ...

Much has been written about the $572M verdict against Johnson & Johnson ( JNJ ) on August 26 for its role in the opioid epidemic in Oklahoma. Not much, however, has dissected the actual 42-page ruling by Judge Thad Balkman systematically, which I will attempt to do here. Based on the J...

The FDA approves the use of a TSK STERiGLIDE cannula with Allergan's (NYSE: AGN ) Juvéderm VOLUMA XC hyaluronic acid gel dermal filler for cheek augmentation in the mid-face of adults at least 21 years old.  More news on: Allergan plc, Healthcare stocks news, Consumer stoc...

DUBLIN , Sept. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA ® XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek augmentation to...

This article is part of a series that provides an ongoing analysis of the changes made to Southeastern Asset Management’s 13F portfolio on a quarterly basis. It is based on Southeastern’s regulatory 13F Form filed on 08/14/2019. Please visit our " Tracking Mason Hawkins’...

DUBLIN , Aug. 30, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the Company and its U.S. subsidiaries have reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid multidistrict litigation. As part of the agreement, Allergan wil...